Cooper Companies said President and CEO Albert G. White III resigned from the Board and his offices effective October 27, 2026, and will advise the company through April 1, 2027. Walter M. Rosebrough, Jr. was appointed interim Executive Chair while a CEO Search Committee seeks a permanent chief executive. Shlomo Nachman will join the Board December 8, 2026, and three directors will not stand for reelection in 2027.
COO · Cooper Companies, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Sep 9, 2026TL;DR. Non-GAAP EPS rose 4% to $1.15, free cash flow increased 66% to $273.0 million, and CooperSurgical delivered 3% organic growth alongside expanded buybacks and productivity-driven operating margin improvement. CooperVision remained flat, non-GAAP gross margin declined 60 basis points year over year, and Q4 faces continued inventory effects, lower CooperVision guidance and pressure from investment, foreign exchange and lower tariff refunds.
- + Non-GAAP EPS increased 4% to $1.15 and exceeded consensus expectations for an 11th consecutive quarter.
- + Free cash flow increased 66% to $273.0 million.
- + A favorable HMRC examination produced a $307.2 million discrete tax benefit.
- + CooperSurgical revenue increased 3% organically to $349.2 million.
- + The share repurchase authorization increased from $2 billion to $3 billion, leaving approximately $1.5 billion available.
- + Operating margin increased 30 basis points year over year to 26.3% on productivity improvements.
- − CooperVision revenue was flat year over year at $717.0 million.
- − Non-GAAP gross margin declined 60 basis points year over year because of higher manufacturing costs and unfavorable foreign exchange.
- − Q4 CooperVision revenue is expected to be down 2% to flat organically.
- − U.S. channel inventory reduction weighed on Q3 results and will continue to affect Q4.
- − Greater CooperVision investment, additional foreign-exchange headwinds and lower tariff refunds are expected to pressure Q4 gross and operating margins.
- − The non-GAAP effective tax rate is expected to rise from roughly 15 and a half this year to roughly 17 and a half in fiscal 2027.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Fertility | $141.2M | FY2026 Q3 | +3.0% |
|
|
|||
| Free cash flow | $273M | Third Quarter 2026 | — |
| Non-GAAP diluted EPS non-GAAP | $1.15 | Third Quarter 2026 | — |
| Non-GAAP gross margin non-GAAP | 67% | Third Quarter 2026 | — |
| Non-GAAP net income non-GAAP | $221.5M | Three Months Ended July 31 | — |
| Non-GAAP operating income non-GAAP | $280.7M | Three Months Ended July 31 | — |
| Non-GAAP operating margin non-GAAP | 26% | Third Quarter 2026 | — |
| Office and surgical | $208M | FY2026 Q3 | +1.6% |
|
|
|||
| Sphere, other | $353.2M | FY2026 Q3 | -1.8% |
|
|
|||
| Toric and multifocal | $363.8M | FY2026 Q3 | +1.4% |
|
|
|||
| Share repurchases | $13.1M | the three months ended April 30, 2026 filing | — |
| Shares repurchased | 0.2M | the three months ended April 30, 2026 filing | — |
| Weighted average price per share | $75.84 | the three months ended April 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
COO
this stock
Cooper Companies, Inc.
|
$11.55B | -25.9% | +18.4% | 20.8 | 5.3% |
|
ISRG
Intuitive Surgical Inc
|
$145.92B | -25.7% | +20.5% | 51.0 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.86B | — | +8.2% | 95.6 | 3.0% |
|
MDLN
Medline Inc.
|
$51.51B | -6.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$36.15B | -4.5% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 27, 2026
- This year
- 12
Cooper Companies said President and CEO Albert G. White III resigned from the Board and his offices effective October 27, 2026, and will advise the company through April 1, 2027. Walter M. Rosebrough, Jr. was appointed interim Executive Chair while a CEO Search Committee seeks a permanent chief executive. Shlomo Nachman will join the Board December 8, 2026, and three directors will not stand for reelection in 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| COO | -3.5% | +3.0% | -0.8% | +2.0% | -25.9% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +0.4% | +8.6% | +2.7% | +5.4% | -33.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.